Spyre RA drug trial misses internal bar despite some efficacy

August 25, 2026 4:01 PM

Spyre Therapeutics (NASDAQ: SYRE) announced topline results from the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial evaluating SPY072 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found